The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 04, 2018

Filed:

Aug. 28, 2015
Applicants:

Calixar, Lyons, FR;

Université Claude Bernard Lyon 1, Villeurbanne, FR;

Hospices Civils DE Lyon, Lyons, FR;

Inserm, Paris, FR;

Inventors:

Manuel Rosa-Calatrava, Lyons, FR;

Aurélien Traversier, Vénissieux, FR;

Élodie Desuzinges-Mandon, Saint-Genis-Laval, FR;

Emmanuel Dejean, Solaize, FR;

Assignees:

CALIXAR, Lyons, FR;

UNIVERSITÉ CLAUD BERNARD LYON 1, Villeurbanne, FR;

HOSPICES CIVILS DE LYON, Lyons, FR;

INSERM, Paris, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 7/02 (2006.01); A61K 39/145 (2006.01); C07C 39/17 (2006.01); C12N 7/04 (2006.01); A61K 39/12 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C12N 7/04 (2013.01); A61K 39/12 (2013.01); A61K 39/145 (2013.01); C07C 39/17 (2013.01); C12N 7/00 (2013.01); A61K 2039/5252 (2013.01); C12N 2760/16134 (2013.01); C12N 2760/16151 (2013.01);
Abstract

The present invention relates to a method for preparing a vaccine antigen, which includes a step of fragmenting a biological membrane associated with said vaccine antigen by treating said biological membrane with at least one calixarene of formula (II): wherein: X is a —(CH2)-CO2Y group and Y is an alkaline metal or one of the pharmaceutically acceptable salts thereof, wherein said resulting vaccine antigen also includes a fragment of the biological membrane associated with said antigen. The present invention also relates to a vaccine that can be produced by implementing the method, including a calixarene of formula (II) in carrier format, with a quantity of 0.1 to 1,000 μg in the total weight of the vaccine. The present invention further relates to the use of a calixarene as defined above for the preparation of a vaccine or a vaccine antigen, and to the vaccine for use as a drug in the treatment or prevention of an infectious disease.


Find Patent Forward Citations

Loading…